Risk of Drug-Drug Interactions in Patients With HIV and Cancer
As many as 1 in 4 patients receiving treatment for cancer and HIV may be at risk of experiencing drug-drug interactions, according to researchers.
As many as 1 in 4 patients receiving treatment for cancer and HIV may be at risk of experiencing drug-drug interactions, according to researchers.
After the BCG shortage began, patients with non-muscle invasive bladder cancer were less likely to receive a full course of induction with any drug.
Total hospital costs related to radical cystectomy are higher in the West than in all other regions of the United States, a study suggests.
Combination avelumab and axitinib has shown long-term activity in previously untreated patients with advanced renal cell carcinoma.
After physicians voiced concerns about an active surveillance recommendation, the NCCN panel revised the guidelines.